IP Library Granted Patent US 10,464,980
Granted Patent B2
US 10,464,980 · App. 11/377,703 · Granted Nov 5, 2019

Compositions including different types of transfer factor

Inventors: David Lisonbee (Orem, UT); William J. Hennen (Eagle Mountain, UT); F. Joseph Daugherty (Omaha, NE)
Assignee: 4Life Patents, LLC
C07K14/52A61J3/074A61K35/20A61K35/57C07K14/465A61K35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,464,980
App. No.
11/377,703
Granted
Nov 5, 2019
Kind
B2
Abstract

A composition for eliciting a T-cell mediated immune response in a subject includes transfer factor from at least two different types of source animals. For example, the composition may include mammalian transfer factor and nonmammalian transfer factor. An example of the composition includes a combination of a colostrum-derived product, which includes the mammalian transfer factor, and an egg-derived product, which includes the nonmammalian transfer factor. Additionally, the egg-derived product may be substantially free of fat. Methods for forming the composition and eliciting T-cell mediated immune responses in subjects that have been treated with the composition are also disclosed.

Claims (25)

1. A composition consisting of:

a first quantity of bovine colostrum comprising mammalian transfer factor; and

a second quantity of chicken egg yolk comprising avian transfer factor, the second quantity mixed with the first quantity,

the bovine colostrum and the chicken egg yolk being selected, and amounts and relative proportions of the first quantity and the second quantity being tailored to synergistically elicit an elevated cell-mediated immune response in a treated animal.

2. The composition of claim 1 , wherein the first quantity of bovine colostrum is a fraction or an extract of bovine colostrum.

3. The composition of claim 2 , wherein the fraction of the bovine colostrum is substantially free of fat.

4. The composition of claim 3 , wherein the fraction of the bovine colostrum is substantially free of at least one of casein, cells, cell debris, antibodies, and allergenic agents.

5. The composition of claim 1 , wherein the mammalian transfer factor of the bovine colostrum is capable of eliciting a non-specific cell-mediated immune response and the avian transfer factor of the chicken egg yolk is capable of eliciting a specific cell-mediated immune response against one or more predetermined antigens.

6. The composition of claim 1 , wherein the relative proportions of the first quantity and the second quantity are further tailored to maintain the elevated cell-mediated immune response for a period of at least 48 hours.

7. The composition of claim 1 , wherein the bovine colostrum is dried bovine colostrum and the chicken egg yolk is dried chicken egg yolk.

8. A composition consisting of:

bovine colostrum or an extract or fraction thereof with mammalian transfer factor; and

chicken egg yolk or an extract or fraction thereof with avian transfer factor,

amounts and relative proportions of the bovine colostrum or the extract or fraction thereof and the chicken egg yolk or the extract or fraction thereof being tailored to synergistically elicit an elevated cell-mediated immune response in a treated human.

9. The composition of claim 8 , wherein the relative proportions of the bovine colostrum or the extract or fraction thereof and the chicken egg yolk or the extract or fraction thereof are further tailored to maintain the elevated cell-mediated immune response for a period of at least 48 hours.

10. The composition of claim 8 , wherein the bovine colostrum or the extract or fraction thereof and the chicken egg yolk or the extract or fraction thereof are in dry form.

11. A composition, comprising:

a measured amount of a composition for eliciting a cell-mediated immune response in a treated subject, the composition consisting of:

a mammalian transfer factor-containing component; and

an avian transfer factor-containing component,

amounts and relative proportions of the mammalian transfer factor-containing component and the avian transfer factor-containing component being selected to synergistically elicit an elevated cell-mediated immune response in the treated subject.

12. The composition of claim 11 , wherein:

the mammalian transfer factor-containing component is bovine colostrum or derived from bovine colostrum; and

the avian transfer factor-containing component is chicken egg yolk or derived from chicken egg yolk.

13. The composition of claim 11 , wherein the mammalian transfer factor-containing component and the avian transfer factor-containing component are in dry form.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR TO ALSO INCLUDE 4LIFE PATENTS, LLC PREVIOUSLY RECORDED ON REEL 021805 FRAME 867. ASSIGNOR(S) HEREBY CONFIRMS THE GRANT OF SECURITY INTEREST FROM 4LIFE RESEARCH, LLC AND 4LIFE PATENTS, LLC TO CHASE CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT. Recorded Nov 13, 2008
From: 4LIFE RESEARCH, LLC; 4LIFE PATENTS, LLC
To: CHASE CAPITAL CORPORATION
Reel/Frame 021824/0333 →
SECURITY AGREEMENT Recorded Nov 11, 2008
From: 4LIFE RESEARCH, LLC
To: CHASE CAPITAL CORPORATION
Reel/Frame 021805/0867 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2006
From: LISONBEE, DAVID; DAUGHERTY, F. JOSEPH
To: 4LIFE PATENTS, LLC
Reel/Frame 018462/0472 →
Continuity (3)
Continuation In Part PCTUS2004030307 · Sep 15, 2004
Continuation 10663353 · Sep 15, 2003
Related Publication 20070053919A1 · Mar 8, 2007